论文部分内容阅读
目的分析和评估急性白血病Bcl－2、P170、CD_(34)表达的临床预测价值。方法用ABC免疫细胞化学法检测42例急性白血病Bcl－2、P170、CD_(34)的表达。结果Bcl－2、P170、CD_(34)高表达的急性白血病完全缓解（CR）率低于低表达或不表达者（45．5％V77．4％，50．0％v78．6％，57．1％v75．0％，P＜0．05），未CR和早期复发率高，分别为81．8％，78．6％，64．3％。化疗2个疗程达CR者Bcl－2、P170的高表达率高于化疗1个疗程达CR者（36．4％v5．6％，45．5％v11．1％，P＜0．05）。Bcl－2与急性白血病预后的阳性符合率为90．9％，略高于P170、CD_(34)。同时检测3项指标的阳性、阴性及总符合率分别为100％、80％及84．6％。结论Bcl－2、P170、CD_(34)的高表达均预示急性白血病的预后不良。Bcl－2可作为预测急性白血病疗效、预后较敏感的指标，多指标联合检测预测价值更高。
Objective To analyze and evaluate the clinical predictive value of Bcl-2, P170 and CD_(34) expression in acute leukemia. Methods The expression of Bcl-2, P170 and CD_(34) in 42 cases of acute leukemia was detected by ABC immunocytochemistry. Results The complete remission (CR) rate of acute leukemia with high expression of Bcl-2, P170 and CD_(34) was lower than those with low or no expression (45.5%V77.4%, 50.0%v78.6%, 57 .1%v75.0%, P<0.05), without CR and early recurrence rates were 81.8%, 78.6%, 64.3%. The high expression rate of Bcl-2 and P170 in patients who received CR after two cycles of chemotherapy was higher than that in CR after one course of chemotherapy (36.4% v5.6%, 45.5%v11.1%, P<0.05). . The positive coincidence rate of Bcl-2 and acute leukemia was 90.9%, slightly higher than that of P170 and CD_(34). At the same time, the positive, negative and total compliance rates of the three indicators were 100%, 80% and 84.6%, respectively. Conclusion The high expression of Bcl-2, P170 and CD_(34) all predicts the poor prognosis of acute leukemia. Bcl-2 can be used as an index to predict the curative effect and prognosis of acute leukemia, and the multi-index combined detection has higher predictive value.